Trial Profile
A Study Evaluating Diagnostic Efficacy And Safety Of Macimorelin (Macrilen) In Pediatric Patients Patients At Least Three Years Old
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2017
Price :
$35
*
At a glance
- Drugs Macimorelin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions; Diagnostic use
- 30 Mar 2017 New trial record
- 07 Mar 2017 According to an Aeterna Zentaris media release, the Pediatric Committee (PDCO) of the European Medicines Agency agreed to Aeterna Zentaris Pediatric Investigation Plan (PIP) and also agreed that the company may defer conducting the studies defined in the PIP until it files an MAA for Macimorelin for the treatment of somatotropin-deficiency in adults.